


Alzheimer's disease susceptibility and Folate

*Prof. Vandana Rai
Department of Biotechnology
Veer Bahadur Singh Purvanchal University
Jaunpur-222003(UP)-India*

Alzheimer's Disease

- **Alzheimer's disease** is a progressive, unremitting, neurodegenerative disorder that affects wide areas of the cerebral cortex and hippocampus.
- Subtle losses of memory or changes in behaviour are the first outward signs of Alzheimer's disease.
- Despite much effort, the condition's cause remains uncertain and no effective treatment yet exists.



Progression of Alzheimer's Disease



10 Symptoms of Alzheimer's

1. Memory loss that disrupts daily life
2. Challenges in planning or solving problems
3. Difficulty completing familiar tasks
4. Confusion with time or place
5. Trouble understanding visual images and spatial relationships
6. New problems with words in speaking or writing
7. Misplacing things and losing the ability to retrace steps
8. Decreased or poor judgment
9. Withdrawal from work or social activities
10. Changes in mood and personality

Alzheimer's Disease

When nerve cells in key areas of the brain are damaged or destroyed.

These changes disrupt the normal flow of information between body and brain resulting in a steady decline in mental function.



Drew L. Nature 2018;559:S2-3


MICROSCOPIC CHANGES

Two hallmarks of Alzheimer's disease are visible only under the microscope.

Accumulations of the peptide amyloid- β , known as plaques, form between neurons. Microtubule-associated protein tau aggregates into neurofibrillary tangles inside neurons, and these structures persist after neurons have died.


By the time that a person begins to experience the symptoms of Alzheimer's disease, the condition is already well-established in the brain.

- The accumulation of amyloid- β , generally thought to be the first step in disease progression, could precede symptoms by 10–15 years.
- Tau accumulation occurs later, much closer to the onset of neurodegeneration.




Worldwide, at least 44 million people are living with AD, making the disease a global health crisis and it is increasing at an alarming rate

A growing global problem



Data source: 'The Global Impact of Dementia 2013–2050', Alzheimer's Disease International (December 2013).


The Global Death Impact of Alzheimer's Disease



India has the third highest caseload in the world, after China and the US.

Dementia – Steep increase in numbers

Number of People with Dementia in India (in millions)



- In India, more than 4 million people are estimated to be suffering from Alzheimer's and other forms of dementia.

- Number is expected to double by 2030

Only 10% of cases are diagnosed



अलजाइमरस एण्ड रिलेटेड डिसऑर्डरस सोसाइटी ऑफ इंडिया
ALZHEIMER'S & RELATED DISORDERS SOCIETY OF INDIA




- **ARDSI National Administrative Office
Harmony Home, Thrissur**
- **Respite Care Centre, Thrissur**
- **Cochin Harmony Home, Cochin**
- **Comprehensive Day Care Centre, Cochin**
- **Malabar Harmony Home, Calicut**
- **ARDSI - Kolkata (Calcutta) Chapter**
- **Snehasadanam, Trivandrum**
- **Day Care Centre, Delhi**
- **Nightingale Medical Trust, Bangalore**



RISK FACTORS

GENETICS

- Around **1%** of cases of Alzheimer's disease are caused by mutations in the genes *which affect amyloid-processing*
- *APP,*
- *PSEN1 or PSEN2,*



Gender



The overall incidence of Alzheimer's disease in women is up to twice that of men.

LIFESTYLE


- Potentially modifiable risk factors for Alzheimer's disease have been identified.
- Diabetes
- Obesity
- Depression
- Smoking and
- Low educational attainment.



Stages of Alzheimer Disease

Stages	Patients condition	Duration	Brain regions	Symptoms	Disease
Stage 1	Normal	7 years	Disease begins in Medial Temporal lobe	Short Term memory loss	Mild Cognitive impairments
Stage 2	Normal age forgetfulness				
Stage 3	Mild cognitive impairments				
Stage 4	A diagnosis of Alzheimer's disease is possible, patients have trouble with memory and every day task	2 years	Disease spreads to lateral Temporal and parital lobes	Reading problems, Poor Object recognition, Poor direction sense	Mild Alzheimer's disease
Stage 5	Patients can no longer live independently as their memory and ability to communicate deteriorates	2 years	Disease spreads to frontal lobe	Poor Judgement, Impulsivity, Short Attention	Moderate Alzheimer's disease
Stage 6	Memory is severely impaired, patients confused, Patients will need family members for personal hygiene	3 Years	Disease Spreads to Occipital lobe	Visual problems	Severe Alzheimer's disease
Stage 7	Patient can no longer respond to their environment and become infantile				

Quality of life of patients with Alzheimer's disease.



Schematic depiction of relative rates of change of cognitive impairment, social dependence and motor abnormalities that adversely affect the general quality of life in people who develop dementia due to Alzheimer's disease.

Diagnostic and Clinical Tests for Alzheimer's Disease

Query	Pathogenesis	Pathophysiology	Biomarkers	Pathology	Clinical and cognitive
Assay	Genetic testing of risk factors and protective factors	A β , tau and APOE metabolism in the brain, FDG PET and functional connectivity	Biochemical measures in the CSF	A β and tau PET imaging, and structural MRI	CDR-SB and neurological examination, and psychometrics
Result	Mutations in <i>PSEN1</i> , <i>PSEN2</i> , <i>APP</i> or <i>APOE</i> allele (2, 3 or 4)	Overproduction or impaired clearance of A β and aggregation of tau in the brain Hypometabolism in the parieto-occipital cortex	Decreased A β 42 levels, and increased T-tau and P-tau levels in the CSF	A β aggregation, tau aggregation, and hippocampal and cortical atrophy	Memory, attention, executive cognitive dysfunction, functional impairment and dementia staging

A β , amyloid- β ; APOE, apolipoprotein E; APP, amyloid, precursor protein; CDR-SB, Clinical Dementia Rating-Sum of Boxes; CSF, cerebrospinal fluid; FDG, fluorodeoxyglucose; P-tau, phosphorylated tau; PSEN1, presenilin 1; PSEN2, presenilin 2; T-tau, total tau.

Alzheimer's disease. *Nat Rev Dis Primers* **1**, 15059 (2015)

*Confirmed genetic factors predisposing to Alzheimer's disease:
relationships to the b-amyloid phenotype*

Chromosome	Gene Defect	Phenotype
21	β -APP mutations	↑ Production of all A β peptides or A β_{40} peptides
19	ApoE4 polymorphism	↑ Density of A β plaques and vascular deposits
14	Presenilin 1 mutations	↑ Production of A β_{42} peptides
1	Presenilin 2 mutation	↑ Production of A β_{42} peptides

β -APP, β -amyloid precursor protein; A β , amyloid β -protein.

Rocchi et al., Brain Research Bulletin 61 (2003) 1-24

Alzheimer's Disease and Genes

(i)Chromosome 21, APP = amyloid precursor protein gene (-> a protease inhibitor in the membrane)

-Incorrect processing -> ~40aa beta-amyloid.

-May poison cholinergic neurons

-The inherited mutation in some families, but also in many sporadic cases of Alzheimer's

--APP Mutations Increase the Production of Ab42 Peptides

(ii)Chromosome. 14q, Presenilin 1 (PSEN1)

--Early onset, inherited

(iii) chromosome 1, Presenilin 2 (PSEN2)

Presenilin Mutations Increase the Production of Ab42 Peptides

(iv)Chrom. 19, apoE (apolipoprotein E) gene

-3 major alleles (APO E2, E3, and E4)

- Apolipoprotein e4 haplotype is a genetic risk factor

-Inheritance of ApoE4 Alleles Increases Steady-State Levels of Ab Peptides in the Brain


- Late onset, inherited; also sporadic

-The mutation apoE4 product binds tightly to beta-amyloid (**APO E4: Arg112 / Arg158**)

Methylenetetrahydrofolate Reductase (MTHFR)


One of the most critical enzymes involved in **folate metabolism**.

- It irreversibly catalyzes the conversion of **5,10-methylenetetrahydrofolate** to **5-methyltetrahydrofolate(5-THF)**.
- 5-THF donates methyl group for the conversion of **homocysteine** to **methionine**, which is further converted into **S-adenosylmethionine(SAM)**.
- **SAM** is the main methyl group donor for all cellular methylation reactions.
- **Human MTHFR enzyme is a 77-kilodalton protein.**





1p36.22



11 Exons

C677T Polymorphism

A1298C Polymorphism

. TCT GCG GGA G**C**C GAT TTC ATC..

. TCT GCG GGA G**T**C GAT TTC ATC..

. UCU GCG GGA G**C**C GAU UUC AUC..

. UCU GCG GGA G**U**C GAU UUC AUC..

.. S A G **A** D F I.....

(Alanine)

222

.. S A G **V** D F I.....

(Valine)

DNA

mRNA

Protein

...ACC AGT GAA G**A**A AGT GTC TTT..

....ACC AGT GAA G**C**A AGT GTC TTT..

....ACC AGU GAA G**A**A AGU GUC UUU

....ACC AGU GAA G**C**A AGU GUC UUU

.... T S E **E** S V F...


(Glutamate)

429

..... T S E **A** S V F...


(Alanine)

MTHFR Gene Variants




- Variant MTHFR reduces the conversion of 5, 10-methylene THF to 5-methyl THF, and elevates plasma homocysteine concentration.
- The reduction in enzyme activity associated with the C677T MTHFR polymorphism raises the dietary requirement for folic acid to maintain normal remethylation of homocysteine to methionine.

T allele frequency



Frequency of C allele (A1298C)



MTHFR Mutation Symptoms

**Fatigue, brain fog, anxiety, depression, insomnia, headache,
migraine, obesity, joint and muscle pains**

MTHFR and Alzheimer Disease

Mol Neurobiol (2017) 54:1173–1186
DOI 10.1007/s12035-016-9722-8



Methylenetetrahydrofolate Reductase (MTHFR) C677T Polymorphism and Alzheimer Disease Risk: a Meta-Analysis

Vandana Rai¹

OR (95%CI),p
TT vs CC: OR= 1.31(1.16–1.48),0.001
Association=Yes

Ind J Clin Biochem
DOI 10.1007/s12291-015-0512-2



REVIEW ARTICLE


Folate Pathway Gene Methylenetetrahydrofolate Reductase C677T Polymorphism and Alzheimer Disease Risk in Asian Population

Vandana Rai¹




Genetics and Alzheimer's Disease

	Early-Onset AD (Dominantly Inherited)	Early-Onset AD (Complex Inheritance)	Late-Onset AD (Complex Inheritance)
Cause:	Inherited Genetic Mutations	Genetic and Environmental Risk Factors	Genetic and Environmental Risk Factors
Age at Onset:	Usually 30-60 years	<65 years	>65 years
Proportion of Cases:	~1%	~4%	~95%



Five ways you can reduce your risk of AD



<https://alz.org.sg/5ways/>

Folate deficiency in older individuals

- **Intestinal malabsorption** –
 - Atrophic gastritis
 - Intestinal diseases (Crohn's disease, celiac disease)
 - Gastric and intestinal resection
- **Reduced dietary intake** (due to decreased sensory function and appetite, dysphagia)
- **Therapeutic drugs** (inhibitors of gastric acid secretion, antiepileptics)
- **Alcoholism**
- **Genetic polymorphisms** in enzymes involved in one-carbon metabolism
(e.g., methylene tetrahydrofolate reductase (MTHFR))

Folate deficiency symptoms

- Fatigue,
- Grey hair,
- Mouth sores,
- swollen tongue,
- Forget fullness,
- depression,
- loss of appetite,
- concentration problems,
- birth defects, and
- poor growth

Food rich in folate

- Avocado,
- Asparagus,
- Broccoli
- Cauliflower,
- Beets,
- Okra,
- Capsicum, Beans,
- Pea,
- Orange,
- Pappaya,
- Nuts and
- Lentis etc.

The United States Public Health Service recommended in 1992 that all women capable of becoming pregnant consume 400 μg folic acid daily.

In 1998, folic acid fortification of all enriched cereal grain product flour was fully implemented in the **United States and Canada**.

Recent estimates show that in the United States and Canada, the additional intake of about 100 to 150 $\mu\text{g}/\text{day}$ of folic acid through food fortification has been effective in-

- **reducing the prevalence of NTDs at birth** and
- **increasing blood folate concentrations in both countries.**


Fortification of wheat flour has a proven record of prevention in other developed countries

Wald, N.J. et al. Public Health Rev (2018) 39: 2.


Specific features make low folate a probable candidate for long-term contribution to AD development.

Folate deficiency induces several pathophysiologic changes supposed to be pathogenetic in Alzheimer's dementia (AD) like

1. mitochondrial dysfunction leading to oxidative stress
2. loss of calcium regulation
3. neuronal and synaptic impairment
4. accumulation of hyperphosphorylated tau and β -amyloid.



Folate deficiency and Alzheimer's dementia. For depicting this figure, the following references were used: (Fenech 2010; Fleming et al. 2011; Fuso and Scarpa 2011; Ho et al. 2003; Kruman et al. 2002; Kruman et al. 2005; Mattson and Shea 2003; Pierrot et al. 2006; Sontag et al. 2007, 2008). Only direct folate and/or homocysteine- dependent actions are considered. dUMP deoxy-uridine monophosphate, dTMP deoxy-tymidine monophosphat, mtDNA mitochondriale DNA, APP amyloid precursor protein, BACE1 beta site amyloid precursor protein cleavage enzyme 1, PSEN1 presenilin1, PP2A protein phosphatase 2A



1. Folate deficiency and homocysteine
2. Expression of β and γ secretases increased by regulated by methyl donor availability
3. Tau phosphorylation
4. Folate deficiency alters calcium dynamics and stimulates apoptosis
5. Folate deficiency and increases oxidative stress
6. Methyl donors are required for maintenance of neurotransmitters
7. Evidence from epidemiological studies

THF Tetrahydrofolate; 5,10-MeTHF 5,10-methylene tetrahydrofolate; 5 MeTHF 5-Methyl tetrahydrofolate; Hcy homocysteine; SAM S-adenosyl methionine; S-adenosyl homocysteine; MS methionine synthase; GSH glutathione; GSSG Glutathione disulphide; PP2A Protein phosphatase 2; PSEN1 Presenilin-1; BACE1 Beta-secretase 1; APP amyloid precursor protein; AB β -amyloid; P-tau phosphorylated tau; NFTs neurofibrillary tangles; ROS reactive oxygen species.

Treatment (none)

- April 2002, mice, vaccination with beta-amyloid helps

(i)Cholinesterase inhibitors.

Inhibitors of neurotransmitter acetylcholinesterase delay symptoms but don't cure.

These drugs work by boosting levels of cell-to-cell communication by preserving a chemical messenger that is depleted in the brain by Alzheimer's disease. Commonly prescribed cholinesterase inhibitors include donepezil (Aricept), galantamine (Razadyne) and rivastigmine (Exelon).

(ii)Memantine (Namenda). This drug works in another brain cell communication network and slows the progression of symptoms with moderate to severe Alzheimer's disease.